Date
|
Event
|
| December 2010 |
52nd ASH Annual Meeting and Exposition |
|
Posters presentations by:
Dr. Anas Younes on ‘Phase 1 Study of a Novel oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes’;
Dr. Srdan Verstovsek on ‘Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis’;
Dr. Guillermo Garcia-Manero on ‘Phase 1 Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies’
Dr. Younes, Dr. Verstovsek and Dr. Garcia-Manero are from the University of Texas, MD Anderson Cancer Center. The 52nd ASH Annual Meeting and Exposition will be held in Orlando, Florida from 4-7 December 2010.
Poster Title:
Session Name:
Session:
Venue:
Room:
Poster Board:
|
Phase 1 Study of a Novel oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma:
Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes
Lymphoma – Chemotherapy, excluding Pre-Clinical Models: Poster II
5 Dec 2010, 6:00-8:00pm
Orange Country Convention Center
Hall A3/A4
II-710
|
Poster Title:
Session Name:
Session:
Venue:
Room:
Poster Board:
|
Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis
Myeloproliferative Syndromes: Poster II
5 Dec 2010, 6:00-8:00pm
Orange Country Convention Center
Hall A3/A4
II-962
|
Poster Title:
Session Name:
Session:
Venue:
Room:
Poster Board:
|
Phase 1 Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies.
Acute Myeloid Leukemia – Therapy, excluding Transplantation: Poster III
6 Dec 2010, 6:00-8:00pm
Orange Country Convention Center
Hall A3/A4
III-71
|
|
| November 2010 |
22nd EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’ |
|
Dr. Veronica Diermayr, Team Leader at S*BIO, presented a poster during the ‘Molecular-targeted therapies-clinical trials’ session at the 22nd EORTC-NCI-AACR ‘Molecular Targets and Cancer Therapeutics’ Symposium held in Berlin, Germany from 16-19 November 2010.
|
| November 2010 |
22nd EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’ |
|
Dr. Francis Burrows, Head, Oncology Biology at Tragara Pharmaceuticals Inc., presented a poster during the session ‘Molecular-targeted therapies-preclinical’ at the 22nd EORTC-NCI-AACR ‘Molecular Targets and Cancer Therapeutics’ Symposium. TG02 is also known as SB1317 and is currently licensed by S*BIO to Tragara. The symposium was held in Berlin, Germany from 16-19 November 2010.
|
| November 2010 |
74th ACR/ARHP Annual Scientific Meeting |
|
Dr. Kee Chuan Goh, Group Leader, Drug Discovery Biology of S*BIO, presented on “SB1578, a Novel Selective JAK2 Inhibitor, Is Highly Efficacious in Rodent Models of Rheumatoid Arthritis” in the session ““Rheumatoid Arthritis – Animal Models: Insight in Pathogenesis and Novel Therapeutic Targets I” at the 74th ACR/ARHP Annual Scientific Meeting. This meeting was held in Atlanta, Georgia from 6-11 November 2010.
|
| October 2010 |
Windhover’s PharmAsia Summit 2010 |
|
Dr. Jan-Anders Karlsson, CEO of S*BIO, participated in a panel discussion entitled: “The Asia Strategy for a Biotech Company: What is the Right Kind of Deal?” at the Windhover’s PharmaAsia Summit. This event was held in San Francisco from 25-26 October 2010.
|
| October 2010 |
BIT’s 8th Annual Congress of Interrnational Drug Discovery Science and Technology (IDDST) |
|
Dr. Haishan Wang, Group Leader of S*BIO, presented “Improving the ADME profile of benzimidazole-based hydroxomates led to the discovery of SB939, a HDAC inhibitor in Phase 2 clinical trials” in the session “Smart Medicinal Chemistry toward NCEs – improving ADME/DMPK profile, reducing DDI/Toxicity, and Overcoming Formulation Difficulties” at BIT’s 8th Annual Congress. The congress was held in Beijing from 23-26 October 2010.
|
| September 2010 |
Sofinnova Japan Biopharma Partnering Conference |
|
Dr. Stephen Keith Rhind, Senior Vice President of S*BIO Corporate Development, presented at the Sofinnova Japan Biopharma Partnering Conference. He highlighted the significant progress made by S*BIO on its various programs. This event was held in Tokyo on 28 September 2010.
|
| September 2010 |
Stifel Nicolaus Healthcare Conference 2010 |
|
Dr. Jan-Anders Karlsson, CEO of S*BIO’s presentation highlighted the significant progress made in S*BIO’s clinical programs at the Stifel Nicolaus Healthcare Conference 2010. This event was held in Boston, Massachusetts from 15-17 September 2010.
|
| September 2010 |
Pharma Licensing Strategies Asia 2010 |
|
Dr. Stephen Keith Rhind, Senior Vice President of S*BIO Corporate Development, participated in a panel discussion entitled “Sourcing the Next Big Collaboration Opportunity” at the Pharma Licensing Strategies Asia conference. This conference was held in Singapore from 14-15 September 2010.
|
| September 2010 |
NUS Pharmacy Medicinal Chemistry Symposium 2010 |
|
Dr. Brian Dymock, S*BIO’s Head of Chemistry, spoke on “Falling off the permeability cliff: balancing molecular properties in the design of potent orally available PDK1 inhibitors for the treatment of cancer” in the session “ADMET Assessment in Drug Discovery” of the NUS Pharmacy Medicinal Chemistry 2010 Symposium. The conference was held at Kent Ridge Guild House, National University of Singapore from 1-2 September 2010.
|
| June 2010 |
15th Congress of the European Hematology Association |
|
Dr. John Seymour, from Peter MacCallum Cancer Centre, East Melbourne, Australia spoke on “First Report of the Phase-1 Study of the Novel Oral JAK2 Inhibitor SB1518 in Patients with Myelofibrosis” at the Myeloproliferative Disorders – Clinical session of the 15th Congress of the European Hematology Association. This event was held in Barcelona from 10-13 June 2010.
|
| June 2010 |
Jefferies 2010 Global Life Sciences Conference |
|
Dr. Jan-Anders Karlsson, CEO of S*BIO, presented at the Jefferies 2010 Global Life Sciences Conference. He highlighted the significant progress made by S*BIO on its various programs. This event was held in New York from 8-11 June 2010.
|
| April 2010 |
AACR 101st Annual Meeting 2010 |
|
Dr. Stefan Hart, Senior Scientist with S*BIO, presented a poster “SB1518, a novel oral JAK2-FLT3 inhibitor, is efficacious in models of acute myeloid leukemia and primary leukemic cells from patients” during the poster session at AACR 101st Annual Meeting 2010 in Washington, DC, 17-21 April 2010.
|
|
Dr. Jeanette Wood, Head of Biology and Dr. Stefan Hart, Senior Scientist with S*BIO, presented a poster “The histone deacetylase inhibitor SB939 acts synergistically with Sorafenib in an orthotopic model of hepatucellular carcinoma” during the poster session at AACR 101st Annual Meeting 2010 in Washington, DC, 17-21 April 2010.
|
|
Dr. Francis Burrows, Head, Oncology Biology at Tragara Pharmaceuticals Inc., presented a poster ”TG02, a novel multi-kinase inhibitor with potent anti-leukemic activity” during the poster session at AACR 101st Annual Meeting 2010 in Washington, DC, 17-21 April 2010. TG02 is also known as SB1317 and is currently licensed to Tragara from S*BIO.
|
| March 2010 |
Drug Discovery Technology World Asia 2010 Conference at BioPharm Asia Convention 2010, Singapore |
|
Dr. Brian Dymock, S*BIO’s Head of Chemistry, spoke on “Impacting Medicinal Chemistry in the hottest areas in cancer: a perspective from Singaporean Biotech” in the session “Technologies in lead discovery and optimization” of the Drug Discovery Technology World Asia 2010 conference. This conference was part of the BioPharm Asia Convention 2010 held at the Raffles Convention Centre, Singapore, 16-19 March 2010.
|
| January 2010 |
UK-Singapore Symposium on Medicinal Chemistry |
|
Dr. Brian Dymock, S*BIO’s Head of Chemistry, spoke on ‘How to make real drugs the Singapore way: fast, furious and fun.’ This event was held at the Matrix, Biopolis, Singapore from 25-26 January 2010.
Dr. P.M. Ramanujulu, Senior Scientist, and Dr. Stéphanie Blanchard, Medicinal Chemistry Scientist of S*BIO, respectively presented the posters ‘Novel inhibitors of PDK1 identified through NMR fragment based screening’ and ‘Purine derivatives as inhibitors of PDK-1’ at the UK-Singapore Symposium on Medicinal Chemistry.
|
| January 2010 |
Biotech Showcase 2010 |
|
Dr. Kantharaj Ethirajulu, S*BIO’s Head of Pre-Clinical Development presentation at Biotech Showcase 2010 highlighted the significant progress made in the company’s clinical programs. The event was held in San Francisco from 12-13 January 2010.
|
Home
